sotalol
DISEASE INTERVENTION COMPARISON RESULTS
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611 Systematic Review, Cochrane Review
IN atrial fibrillation, postoperative, cardiac surgery The Use of
several antiarrhythmics (amiodarone, sotalol, beta-blockers) and pacing
As Prevention, Primary
Is better Than
placebo
To reduce the incidence of atrial fibrillation (OR between 0.26 and 0.49) and possibly (non significant) reduces stroke and lenght of stay
Eur Heart J. 2006 Sep;27(18):2224-31. Epub 2006 Aug 25 Randomized Controlled Trial
IN StudyID: A-COMET-II 2006, atrial fibrillation The Use of
azimilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To prevent, at 6 months, AF recurrence without being stopped because adverse effects: sotalol 33% VS 19% azim VS 15% placebo. Both azimilide and sotalol increased proarrhythmia.
J Am Coll Cardiol. 1990 Mar 1;15(3):698-707 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Antman 1990, atrial fibrillation The Use of
propafenone, sotalol if failure, sequentially
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, adverse effects - at 6 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 1999 Aug 1;84(3):270-7 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Benditt 1999, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, mortality, adverse effects - at 12 months
G Ital Cardiol. 1995 Jan;25(1):51-68 Randomized Controlled Trial
IN StudyID: Carunchio 1995, atrial fibrillation, paroxysmal The Use of
flecainide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adeverse effects - at 12 months
Am Heart J. 2008 Aug;156(2):373.e1-8 Randomized Controlled Trial
IN StudyID: DAPHNE 2008, atrial fibrillation, paroxysmal, sinus node disease The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, atenolol, metoprolol
To reduce AF recurrences
J Am Coll Cardiol. 2000 Feb;35(2 Suppl. A):154A-155A Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To mortality at 1 year
Circulation. 1998 Oct 27;98(17):3326 Suppl. I-633 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Drugs. 1999 Dec;58(6):1043-59 Review (Narrative)
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1998 Oct 27;98(17):66 Suppl. 13-14 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Accessed 2010 August 10 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm Randomized Controlled Trial
IN StudyID: EMERALD 1998, atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 year, AF recurrence. But they did not modified mortality and both increased adverse events and pro-arrhythmia
Heart 2002 Oct;88(4):357-62 Randomized Controlled Trial
IN StudyID: GUSTO 2002, atrial fibrillation The Use of
class I agents, sotalol
As Treatment, Chronic
Is better Than
amiodarone, no treatment
To mortality at 30 days and 12 months
Circulation. 1990 Dec;82(6):1932-9 Randomized Controlled Trial
IN StudyID: Juul-Moller 1990, atrial fibrillation, persistent The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 6 months
Heart 2000 Sep;84(3):251-7 Randomized Controlled Trial
IN StudyID: Kochiadakis-AmSot 2000, atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 to 16 months
Am J Cardiol. 2004 Dec 15;94(12):1563-6 Randomized Controlled Trial
IN StudyID: Kochiadakis-ProSot 2004, atrial fibrillation The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, pro-arrhythmia, AF recurrence, adverse effects - at 18 to 25 months
Z Kardiol 1999 Mar;88(3):195-207 Randomized Controlled Trial
IN StudyID: PAFAC (subordinated publication), atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To mortality, AF recurrence - at 12 months
Eur Heart J. 2004 Aug;25(16):1385-94 Randomized Controlled Trial
IN StudyID: PAFAC, atrial fibrillation, persistent The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, adverse effects, pro-arrhythmia, AF recurrence - at 12 months
Eur Heart J. 2001 Aug;22(16):1504-10 Randomized Controlled Trial
IN StudyID: Plewan 2001, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, bisoprolol
To AF recurrence, pro-arrhythmia - at 12 months
Am J Cardiol. 2003 Aug 15;92(4):468-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005 (subordinated publication), atrial fibrillation The Use of
amiodarone, sotalol
As Treatment, Chronic
Is - Than
placebo
To AF recurrence, a number of parameters as secondary end points - at 12 to 54 months
N Engl J Med. 2005 May 5;352(18):1861-72 Randomized Controlled Trial
IN StudyID: Safe-T 2005, atrial fibrillation, persistent The Use of
amiodarone, sotalol
As Treatment, Chronic
Is better Than
placebo
To mortality, stroke, proarrhythmia, AF recurrence - at 12 months
Am J Cardiol. 1991 Nov 1;68(11):1227-30 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Singh 1991, atrial fibrillation, persistent The Use of
sotalol
As unknow
Is - Than
unknow
To unknow
Arq Bras Cardiol 1998 Jan;70(1):43-9 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SOCESP 1999 (subordinate publication), atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, pro-arrhythmia - at 6 months
Am J Cardiol. 1999 Nov 1;84(9):1033-7 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SOCESP 1999, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, pro-arrhythmia - at 6 months
Z Kardiol (Zeitschrift fur Kardiologie) 1999 Mar;88(3):185-94 Randomized Controlled Trial
IN StudyID: SOPAT (subordinated publication), atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Eur Heart J. 2004 Aug;25(16):1395-404 Randomized Controlled Trial
IN StudyID: SOPAT, atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Am J Cardiol. 1999 Jun 15;83(12):1629-32 Meta-Analysis
IN StudyID: Southworth, existing meta-abalysis, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is equal Than
quinidine
To maintaining sinus rhythm at 6 months, and both agents are superior to control. There is a trend for both agents to increase mortality
Heart. Aug 1999; 82(2):170-5 Cross-Over, Randomized Controlled Trial
IN StudyID: Steeds 1999, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is equal Than
atenolol
To at 1 month: AF recurrence, adverse effects
Am Heart J. 1997 Apr;133(4):441-6 Randomized Controlled Trial
IN StudyID: Wanless 1997, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To time to arrhythmia/AF recurrence, adverse effects - at ? time